1-20 of 28
Michael J. Birrer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

Diane M. Da Silva, Danielle M. Enserro, Jyoti S. Mayadev, Joseph G. Skeate, Koji Matsuo, Huyen Q. Pham, Heather A. Lankes, Katherine M. Moxley, Sharad A. Ghamande, Yvonne G. Lin, Russell J. Schilder, Michael J. Birrer, W. Martin Kast
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5621–5630.
https://doi.org/10.1158/1078-0432.CCR-20-0776
Published: 02 November 2020
View article titled, Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Open the PDF for Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) in another window
Includes: Supplementary data
Journal Articles

Abstract B27: Cellular retinoic acid binding protein 2 (CRABP2) is a novel biomarker and potential therapeutic target for high-grade serous ovarian carcinomas

Yi Feng, Michael Gillette, Eric Kuhn, David Klinkebiel, Marilyn A. Mitchell, Kai Doberstein, Daniele Chaves-Moreira, Sho Sato, Haineng Xu, Brett Bomwell, Michelle S. Hirsch, Carolina Reyes, Adam R. Karpf, Michael J. Birrer, Steven J. Skates, Steven A. Carr, Ronny Drapkin
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): B27.
https://doi.org/10.1158/1557-3265.OVCA19-B27
Published: 01 July 2020
View article titled, Abstract B27: Cellular retinoic acid binding protein 2 (CRABP2) is a novel biomarker and potential therapeutic target for high-grade serous ovarian carcinomas
Journal Articles

Abstract IA06: The Long-Term Ovarian Cancer Survivor Project: A Department of Defense initiative

Michael J. Birrer, Lari Wenzel, Austin Miller, Heather Lankes, Nilsa Ramirez, Giovanni Parmigiani, Samuel Mok, Kenneth Nephew, Thomas Conrads, George Coukos, George L. Maxwell, Giulia Fulci, Mary Scroggins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): IA06.
https://doi.org/10.1158/1557-3265.OVCA19-IA06
Published: 01 July 2020
View article titled, Abstract IA06: The Long-Term Ovarian Cancer Survivor Project: A Department of Defense initiative
Journal Articles

Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers

Jacob J. Kennedy, Shrabanti Chowdhury, Sara R. Savage, Xiaonan Hou, Catherine J. Huntoon, Richard G. Ivey, Qing Yu, Chenwei Lin, Dongqing Huang, Lei Zhao, Uliana J. Voytovich, Regine M. Schoenherr, Zahra Shire, Steven J. Skates, Jeffrey R. Whiteaker, Andrew N. Hoofnagle, Samuel C. Mok, Bing Zhang, Larry M. Karnitz, S. John Weroha, Steven P. Gygi, Scott H. Kaufmann, Pei Wang, Michael J. Birrer, Amanda G. Paulovich
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR02.
https://doi.org/10.1158/1557-3265.OVCA19-PR02
Published: 01 July 2020
View article titled, Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers
Journal Articles

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, J. Chris Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O'Malley, Heidi Gray, Jamie N. Bakkum-Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1288–1296.
https://doi.org/10.1158/1078-0432.CCR-19-0226
Published: 13 March 2020
View article titled, Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Open the PDF for Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218 in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer

Tsz-Lun Yeung, Cecilia S. Leung, Kay-Pong Yip, Jianting Sheng, Long Vien, Laura C. Bover, Michael J. Birrer, Stephen T.C. Wong, Samuel C. Mok
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6417–6428.
https://doi.org/10.1158/1078-0432.CCR-19-0187
Published: 01 November 2019
View article titled, Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
Open the PDF for Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek, Jan Pinkas, Stella K. Kim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1727–1736.
https://doi.org/10.1158/1078-0432.CCR-18-2474
Published: 15 March 2019
View article titled, Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
Open the PDF for Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine in another window
Journal Articles

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Joseph J. Caumanns, Katrien Berns, G. Bea A. Wisman, Rudolf S.N. Fehrmann, Tushar Tomar, Harry Klip, Gert J. Meersma, E. Marielle Hijmans, Annemiek M.C. Gennissen, Evelien W. Duiker, Desiree Weening, Hiroaki Itamochi, Roelof J.C. Kluin, Anna K.L. Reyners, Michael J. Birrer, Helga B. Salvesen, Ignace Vergote, Els van Nieuwenhuysen, James Brenton, E. Ioana Braicu, Jolanta Kupryjanczyk, Beata Spiewankiewicz, Lorenza Mittempergher, René Bernards, Ate G.J. van der Zee, Steven de Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (16): 3928–3940.
https://doi.org/10.1158/1078-0432.CCR-17-3060
Published: 14 August 2018
View article titled, Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Open the PDF for Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom Walsh, Ming K. Lee, Suleyman Gulsuner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Krishnansu S. Tewari, Floor Backes, Robert S. Mannel, Gretchen Glaser, Cheryl Bailey, Stephen Rubin, John Soper, Heather A. Lankes, Nilsa C. Ramirez, Mary Claire King, Michael J. Birrer, Elizabeth M. Swisher
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 777–783.
https://doi.org/10.1158/1078-0432.CCR-17-1327
Published: 14 February 2018
View article titled, Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Open the PDF for Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study in another window
Includes: Supplementary data
Journal Articles

Abstract NTOC-113: TGF–β SIGNALING INHIBITION AS A POTENTIAL APPROACH TO TARGET SUBOPTIMALLY DEBULKED OVARIAN TUMORS

Wei Wei, Michael J. Birrer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-113.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-113
Published: 31 May 2017
View article titled, Abstract NTOC-113: TGF–β SIGNALING INHIBITION AS A POTENTIAL APPROACH TO TARGET SUBOPTIMALLY DEBULKED OVARIAN TUMORS
Journal Articles

Abstract TMEM-040: TUMOR ASSOCIATED MACROPHAGES MEDIATES THE ONCOGENIC EFFECT OF FGF18 IN OVARIAN CANCER

Wei Wei, Michael J. Birrer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): TMEM-040.
https://doi.org/10.1158/1557-3265.OVCASYMP16-TMEM-040
Published: 31 May 2017
View article titled, Abstract TMEM-040: TUMOR ASSOCIATED MACROPHAGES MEDIATES THE ONCOGENIC EFFECT OF FGF18 IN OVARIAN CANCER
Journal Articles

Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.

Maria I. Harrell, Barbara M. Norquist, Tom Walsh, Mark F. Brady, Ming K. Lee, Robert Hershberg, Kimberly R. Kalli, Heather Lankes, Eric Q. Konnick, Colin C. Pritchard, Bradley J. Monk, John K. Chan, Robert Burger, Scott H. Kaufmann, Michael J. Birrer, Elizabeth M. Swisher
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): B71.
https://doi.org/10.1158/1557-3265.OVCA15-B71
Published: 15 January 2016
View article titled, Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.
Journal Articles

Abstract B26: Cell surface expression of CD44v8-10 is associated with good prognosis while cleaved extracellular domain is a marker of poor prognosis in high-grade serous epithelial ovarian cancer.

David Pepin, Amanda Sosulski, Heiko Horn, Lihua Zhang, Caroline Coletti, vinod Vathipadiekal, Cesar M. Castro, Michael J. Birrer, Osamu Nagano, Hidekuyi Saya, Kasper Lage, Patricia K. Donahoe
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): B26.
https://doi.org/10.1158/1557-3265.OVCA15-B26
Published: 15 January 2016
View article titled, Abstract B26: Cell surface expression of CD44v8-10 is associated with good prognosis while cleaved extracellular domain is a marker of poor prognosis in high-grade serous epithelial ovarian cancer.
Journal Articles

Abstract A12: Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology Study.

Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom D. Walsh, Ming K. Lee, Suleyman Gulsuner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Susan A. Davidson, Robert S. Mannel, Paul A. DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary Claire King, Michael J. Birrer, Elizabeth M. Swisher
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): A12.
https://doi.org/10.1158/1557-3265.OVCA15-A12
Published: 15 January 2016
View article titled, Abstract A12: Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology Study.
Journal Articles

Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

Elizabeth Pham, Michael J. Birrer, Scott Eliasof, Edward G. Garmey, Douglas Lazarus, Christina R. Lee, Shan Man, Ursula A. Matulonis, Christian G. Peters, Ping Xu, Carolyn Krasner, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 808–818.
https://doi.org/10.1158/1078-0432.CCR-14-2810
Published: 16 February 2015
View article titled, Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Open the PDF for Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

The role of p21-activated kinase 3 (PAK3) in activating protein 1 (AP-1) induced oncogenesis

Nina Holderness, Howard Donninger, Michael J. Birrer, Virna Leaner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): A36.
https://doi.org/10.1158/DIAG-10-A36
Published: 15 August 2014
View article titled, The role of p21-activated kinase 3 (PAK3) in activating protein 1 (AP-1) induced oncogenesis
Journal Articles

Abstract B58: Connective tissue growth factor (CTGF) as a novel therapeutic target in high grade serous ovarian cancer

Kim Moran-Jones, Rajmohan Murali, David K. Chang, Carol W. Wong, Suzanne M. Spong, Neville F. Hacker, Samuel C. Mok, Michael J. Birrer, Goli Samimi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): B58.
https://doi.org/10.1158/1078-0432.OVCA13-B58
Published: 13 May 2014
View article titled, Abstract B58: Connective tissue growth factor (CTGF) as a novel therapeutic target in high grade serous ovarian cancer
Journal Articles

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Tarrik M. Zaid, Tsz-Lun Yeung, Melissa S. Thompson, Cecilia S. Leung, Tom Harding, Ngai-Na Co, Rosie S. Schmandt, Suet-Ying Kwan, Cristian Rodriguez-Aguay, Gabriel Lopez-Berestein, Anil K. Sood, Kwong-Kwok Wong, Michael J. Birrer, Samuel C. Mok
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 809–820.
https://doi.org/10.1158/1078-0432.CCR-12-2736
Published: 15 February 2013
View article titled, Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Open the PDF for Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

Paul D. P. Pharoah, Rachel T. Palmieri, Susan J. Ramus, Simon A. Gayther, Irene L. Andrulis, Hoda Anton-Culver, Natalia Antonenkova, Antonis C. Antoniou, David Goldgar, Mary S. Beattie, Matthias W. Beckmann, Michael J. Birrer, Natalia Bogdanova, Kelly L. Bolton, Wendy Brewster, Angela Brooks-Wilson, Robert Brown, Ralf Butzow, Trinidad Caldes, Maria Adelaide Caligo, Ian Campbell, Jenny Chang-Claude, Y. Ann Chen, Linda S. Cook, Fergus J. Couch, Daniel W. Cramer, Julie M. Cunningham, Evelyn Despierre, Jennifer A. Doherty, Thilo Dörk, Matthias Dürst, Diana M. Eccles, Arif B. Ekici, Douglas Easton, Peter A. Fasching, Anna de Fazio, David A. Fenstermacher, James M. Flanagan, Brooke L. Fridley, Eitan Friedman, Bo Gao, Olga Sinilnikova, Aleksandra Gentry-Maharaj, Andrew K. Godwin, Ellen L. Goode, Marc T. Goodman, Jenny Gross, Thomas V. O. Hansen, Paul Harnett, Matti Rookus, Tuomas Heikkinen, Rebecca Hein, Claus Høgdall, Estrid Høgdall, Edwin S. Iversen, Anna Jakubowska, Sharon E. Johnatty, Beth Y. Karlan, Noah D. Kauff, Stanley B. Kaye, Georgia Chenevix-Trench, Linda E. Kelemen, Lambertus A. Kiemeney, Susanne Krüger Kjaer, Diether Lambrechts, James P. LaPolla, Conxi Lázaro, Nhu D. Le, Arto Leminen, Karin Leunen, Douglas A. Levine, Yi Lu, Lene Lundvall, Stuart Macgregor, Tamara Marees, Leon F. Massuger, John R. McLaughlin, Usha Menon, Marco Montagna, Kirsten B. Moysich, Steven A. Narod, Katherine L. Nathanson, Lotte Nedergaard, Roberta B. Ness, Heli Nevanlinna, Stefan Nickels, Ana Osorio, Jim Paul, Celeste Leigh Pearce, Catherine M. Phelan, Malcolm C. Pike, Paolo Radice, Mary Anne Rossing, Joellen M. Schildkraut, Thomas A. Sellers, Christian F. Singer, Honglin Song, Daniel O. Stram, Rebecca Sutphen, Annika Lindblom, Kathryn L. Terry, Ya-Yu Tsai, Anne M. van Altena, Ignace Vergote, Robert A. Vierkant, Allison F. Vitonis, Christine Walsh, Shan Wang-Gohrke, Barbara Wappenschmidt, Anna H. Wu, Argyrios Ziogas, Andrew Berchuck, Harvey A. Risch
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3742–3750.
https://doi.org/10.1158/1078-0432.CCR-10-3405
Published: 01 June 2011
View article titled, The Role of <em>KRAS</em> rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing
Open the PDF for The Role of <em>KRAS</em> rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing in another window